SEYED JALALI to Liposomes
This is a "connection" page, showing publications SEYED JALALI has written about Liposomes.
Connection Strength
0.777
-
Encapsulated Checkpoint Blocker Before Chemotherapy: The Optimal Sequence of Anti-CTLA-4 and Doxil Combination Therapy. Int J Nanomedicine. 2020; 15:5279-5288.
Score: 0.157
-
Stimulation of Tumor-Specific Immunity by p5 HER-2/neu Generated Peptide Encapsulated in Nano-liposomes with High Phase Transition Temperature Phospholipids. Curr Drug Deliv. 2017; 14(4):492-502.
Score: 0.123
-
Coadminstration of L. major amastigote class I nuclease (rLmaCIN) with LPD nanoparticles delays the progression of skin lesion and the L. major dissemination to the spleen in BALB/c mice-based experimental setting. Acta Trop. 2016 Jul; 159:211-8.
Score: 0.117
-
Nanoliposome-mediated targeting of antibodies to tumors: IVIG antibodies as a model. Int J Pharm. 2015 Nov 10; 495(1):162-170.
Score: 0.112
-
Effective induction of anti-tumor immunity using p5 HER-2/neu derived peptide encapsulated in fusogenic DOTAP cationic liposomes co-administrated with CpG-ODN. Immunol Lett. 2014 Nov; 162(1 Pt A):87-93.
Score: 0.104
-
Preparation of nanoliposomes containing HER2/neu (P5+435) peptide and evaluation of their immune responses and anti-tumoral effects as a prophylactic vaccine against breast cancer. PLoS One. 2020; 15(12):e0243550.
Score: 0.040
-
P435 HER2/neu-derived peptide conjugated to liposomes containing DOPE as an effective prophylactic vaccine formulation for breast cancer. Artif Cells Nanomed Biotechnol. 2019 Dec; 47(1):665-673.
Score: 0.038
-
Improved tumor accumulation and therapeutic efficacy of CTLA-4-blocking antibody using liposome-encapsulated antibody: In vitro and in vivo studies. Nanomedicine. 2017 Nov; 13(8):2671-2682.
Score: 0.032
-
Poly (I:C)-DOTAP cationic nanoliposome containing multi-epitope HER2-derived peptide promotes vaccine-elicited anti-tumor immunity in a murine model. Immunol Lett. 2016 08; 176:57-64.
Score: 0.029
-
P5 HER2/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer. Cancer Lett. 2014 Dec 01; 355(1):54-60.
Score: 0.026